SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in February 2026 and will also participate in one-on-one investor meetings at each of these conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 (February 11-12, 2026) Lo ...

Erasca (ERAS) has surged 460% over the past year, driven by strong technical momentum. ERAS hit a new 3-year high of $10.92 on Monday. Despite bullish technicals, ERAS has no revenue, is burning cash, and its future hinges on FDA drug approvals. Analyst sentiment is highly speculative, with price targets ranging from $2 to $16. Today’s Featured Stock Valued at $3.25 billion, Erasca (ERAS) is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercia ...

Core Insights - Erasca, Inc. (NASDAQ:ERAS) is recognized as one of the 11 best performing stocks over the last 12 months [1] - Mizuho initiated coverage of Erasca with an 'Outperform' rating and a price target of $16, reflecting confidence in the company's RAS-targeted therapies [2][3] - Guggenheim raised its price target for Erasca from $5 to $12 while maintaining a 'Buy' rating, citing updates on key drug candidates and a recent financing round [4] - Morgan Stanley increased its price target from $4 to $10, reiterating an 'Equal Weight' rating, indicating a cautious but positive outlook [5] Company Developments - Erasca focuses on developing precision oncology therapies targeting RAS/MAPK-driven cancers, founded in 2018 and based in San Diego [5] - The company announced a public offering of 25,875,000 shares, raising $258.8 million in gross proceeds [4] Clinical Pipeline - Mizuho highlighted ERAS-0015 for its tolerable dosing and competitive clinical profile, predicting proof-of-concept establishment in 2026 [3] - Guggenheim projects a 30% chance of success for ERAS-0015 in treating second-line and later non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), with a potential commercial launch in 2030 [4]

Erasca Inc. (NASDAQ:ERAS) is one of the new stocks on the rise. On January 27, Guggenheim increased its price target for Erasca from $5 to $12 with a Buy rating. This decision followed a model update that accounted for recent clinical developments and fresh financing. The firm’s revised valuation includes risk-adjusted revenue estimates for the candidate ERAS-0015, assigning it a 30% probability of success in treating second-line or later NSCLC and PDAC. These projections are centered on an anticipated com ...

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Monday.Shares of Revolution Medicines Inc (NASDAQ:RVMD) dipped 26.1% to $87.02 in pre-market trading.The Wall Street Journal Reported that Merck (NYSE:MRK) is no longer in talks to acquire Revolution Medicines.Revolution Medicines shares dipped 26.1% to $87.02 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Erasca Inc (NASDAQ:ERAS) fell 11.5% to $8.82 in pre-market trading. Erasca anno ...

Erasca Inc. (NASDAQ:ERAS) stock is trading lower on Monday, though there is no news to justify the movement.Erasca stock is trading close to the upper end of its 52-week range of $1.01 – 10.67, according to Benzinga Pro data.The movement came in reaction when U.S. pharma giant Merck & Co., Inc. (NYSE:MRK) reportedly ended discussions to acquire cancer drug developer Revolution Medicines, Inc. (NASDAQ:RVMD) after the two sides disagreed on valuation.The talks had valued Revolution Medicines at roughly $30 bi ...

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The shares of com ...

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offering are to be ...

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.Shares of Netflix Inc (NASDAQ:NFLX) fell sharply in pre-market trading after the company reported fourth-quarter financial results and issued first-quarter guidance below estimates.Netflix reported better-than-expected fourth-quarter financial results Tuesday after market close. Netflix said it sees first-quarter revenue of $12.16 billion versus a Street consensus estimate of $12.19 billion, according to data f ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - Smart Logistics Global Limited (SLGB) is up 198% at $3.67 [3] - Brand Engagement Network, Inc. (BNAI) is up 67% at $10.29 [3] - Boxlight Corporation (BOXL) is up 56% at $1.96 [3] - Moolec Science SA (MLEC) is up 51% at $6.64 [3] - Anteris Technologies Global Corp. (AVR) is up 15% at $6.63 [3] - Hycroft Mining Holding Corporation (HYMC) is up 10% at $47.20 [3] - Nathan's Famous, Inc. (NATH) is up 8% at $100.94 [3] - Progress Software Corporation (PRGS) is up 6% at $41.05 [3] - LightPath Technologies, Inc. (LPTH) is up 5% at $14.81 [3] - ZenaTech, Inc. (ZENA) is up 5% at $4.33 [3] Group 2: Premarket Losers - Top Wealth Group Holding Limited (TWG) is down 29% at $3.81 [4] - Solo Brands, Inc. (SBDS) is down 21% at $5.25 [4] - GlucoTrack, Inc. (GCTK) is down 19% at $3.07 [4] - Galaxy Payroll Group Limited (GLXG) is down 19% at $2.26 [4] - INVO Fertility, Inc. (IVF) is down 13% at $2.04 [4] - Black Titan Corporation (BTTC) is down 11% at $2.11 [4] - Envirotech Vehicles, Inc. (EVTV) is down 10% at $3.30 [4] - Erasca, Inc. (ERAS) is down 6% at $9.21 [4] - ENDRA Life Sciences Inc. (NDRA) is down 6% at $4.31 [4] - Bonk, Inc. (BNKK) is down 6% at $3.74 [4]